Fig. 3

SCD1 inhibition reduces cancer cell proliferation without cytotoxic effect on normal cells. (A) PA-1 and SKOV-3 cells were transfected with SCD1 siRNA (100 nM) or scrambled siRNA (100 nM) as a negative control. After 72 h, the ablation of SCD1 protein was determined by western blot analysis. GAPDH was used as a loading control. (B) PA-1 and SKOV-3 cells were transfected with SCD1 siRNA (100 nM). At 72 h post-transfection, cell viability was analyzed using MTT assay. (C) PA-1 and SKOV-3 cells were treated with various concentrations (0, 5, 10, 20, 50, and 100 nM) of CAY10566 or DMSO (solvent control) for 24–48 h. Cell viability was measured by MTT assay. (D) Bright field microscopy images of patient-derived ovarian cancer organoids A209 (top) and A220 (bottom) after 28 days of culture. Scale bar = 500 μm. (E) Ovarian cancer organoids A209 and A220 were treated with varying concentrations (0, 10, 20, 50, and 100 nM) of CAY10566 or DMSO (solvent control) for 24–48 h. Cell viability was assessed using the organoid MTT assay. (F) CAY10566 were treated in NOSE cell lines (IOSE385 and SNU3236) and peripheral blood mononuclear cells (PBMCs) with different concentrations of CAY10566. After 24–48 h, cell viability was examined by MTT assay. All data were described as mean ± SEM of three independent experiments (**p < 0.01; ***p < 0.001; ****p < 0.0001)